WHITE PAPER: Assessing ddPCR Efficacy in Detecting Rare BRAF Mutations - A Performance Evaluation Study Utilizing Bone Marrow and PBMC Samples
Assessing ddPCR Efficacy in Detecting Rare BRAF Mutations - A Performance Evaluation Study Utilizing Bone Marrow and PBMC Samples
The ddPCR technology partitions samples into numerous droplets, facilitating PCR amplification within each droplet and subsequent quantification. This innovative approach has paved the way for targeted therapies like BRAF inhibitors, designed to disrupt aberrant signaling and inhibit cancer cell growth. Identifying the BRAFV600E mutation not only enhances our understanding of cancer at the molecular level but also enables personalized medicine strategies, providing more precise and effective treatment options based on individual genetic profiles. As research progresses, the significance of this mutation in both diagnosis and therapeutic interventions remains pivotal in oncology.
In this white paper, we outline the validation experiments and performance attributes of quantitative BRAF V600E mutation detection assays conducted using ddPCR at Eurofins Viracor Biopharma.